semaglutide in kidney disease and Survival Outcomes with by... : Clinical Journal of the American Society of Nephrology Acute Kidney Injury Associated With

Implications of the trial results for Ozempic and GLP-1 drugs The results of the trial could expand Ozempics (and eventually other GLP-1 receptor agonists) indications to treat many more conditions for people with type 2 diabetes

Clinical data clearly demonstrates a dose-response relationship, with the 2.4 mg dose producing significantly greater weight loss than lower doses

The FDA has reported adverse-event concerns involving compounded semaglutide and tirzepatide, including dosing errors, gastrointestinal symptoms, and events that required medical attention

It can lead to changes in urination patterns, which are generally temporary

Data exploration and visualization In order to visualize our clusters, we use Uniform Manifold Approximation and Projection (UMAP) 44 which turns our 512 dimensioned embeddings data into a visualizable, two-dimensional representation